"A new report indicates that more than one in five parents of teens aged 12 to 17 (22.3 percent) think what they say has little influence on whether or not their child uses illicit substances, tobacco, or alcohol. This report by the Substanc"...
Patients should be informed that a Registry has been established in order to better understand the variability and progression of Fabry disease in the population as a whole and in women [see Use in Specific Populations], and to monitor and evaluate long term treatment effects of Fabrazyme (agalsidase beta) . The Registry will also monitor the effect of Fabrazyme (agalsidase beta) on pregnant women and their offspring. Patients should be encouraged to participate and advised that their participation is voluntary and may involve long-term follow-up. For more information visit www.fabryregistry.com or call (800) 745-4447.
Last reviewed on RxList: 11/29/2016
This monograph has been modified to include the generic and brand name in many instances.
Additional Fabrazyme Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Parenting and Pregnancy
Get tips for baby and you.